Anti-PD-1 immune checkpoint blockade-based therapy using pembrolizumab in a patient with high-grade glioblastoma. Biomed. Res. Ther. [Internet]. 2023 May 31 [cited 2024 Nov. 15];10(5):5680-5. Available from: https://preservation.bmrat.org/index.php/BMRAT/article/view/809